← All trials
NCT03959241
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 30, 2019
- Primary completion
- Feb 28, 2023
- Completion date
- Feb 29, 2024
- First posted
- —
- Last posted
- —
- Enrollment
- 428
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Medical College of WisconsinLead sponsor
- Center for International Blood and Marrow Transplant ResearchStudy director
- National Cancer Institute (NCI)Collaborator
- National Heart, Lung, and Blood Institute (NHLBI)Collaborator
- National Marrow Donor ProgramCollaborator
- Blood and Marrow Transplant Clinical Trials NetworkCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.